If so, we invite you to participate in brain imaging research at the G. Oppenheimer Center for Neurobiology of Stress and Resilience.
To participate, you must be:
Each visit will include the following:
Compensation:
Women: Earn up to $620 for completing all 5 visits over 12 months at 3 month intervals
Men: Earn up to $150 for a screening visit, an MRI, one stool and blood sample
This study is conducted by Emeran A. Mayer, MD, PhD, G. Oppenheimer Center for Neurobiology of Stress and Resilience.
If interested, please call Tiffany at (310) 825-7217 or tiffanyju@mednet.ucla.edu
Protocol ID: IRB #15-001591 UCLA IRB Approval Date: 12/22/2016 through 10/20/2017 Committee: Medical IRB 3
We invite you to participate in a study to understand how a change in dietary fat influences the brain-gut perception of hunger, food satisfaction and weight loss.
You must be:
During this study, your participation will last up to 14 weeks (including screen) and will include the following:
Compensation: Earn up to $275 and get a digital image of your brain. Study activity is free of charge and parking will be compensated.
This study is conducted by Arpana Gupta, PhD, G. Oppenheimer Center for Neurobiology of Stress and Resilience, in collaboration with Emeran A. Mayer, MD, PhD and in collaboration with Zhaoping Li, MD, PhD, UCLA Center for Human Nutrition.
If interested, please call Tiffany at (310) 825-7217 and refer to the "avocado diet related brain-gut interactions in obesity study."
Protocol ID: IRB #16-000187 UCLA IRB Approval Date: 11/30/2016 through 11/29/2017 Committee: Medical IRB 3, and IRB #16-001157 UCLA IRB Approval Date: 1/30/2017 through 8/9/2017 Committee: Medical IRB 1
We invite you to participate in a study to understand how the gut influences the brains' perception of hunger and changes in food satisfaction.
You must be:
Participation involves:
This study is conducted by Arpana Gupta, PhD, G. Oppenheimer Center for Neurobiology of Stress and Resilience, in collaboration with Emeran A. Mayer, MD, PhD.
If interested, please call Tiffany at (310) 825-7217 and refer to the "brain-gut interactions in obesity study."
Protocol ID: IRB #16-000187 UCLA IRB Approval Date: 11/30/2016 through: 11/29/2017 Committee: Medical IRB 3
You can be part of a microbiome study to collect data using a one time stool test.
The purpose of this study is to:
Study design:
This study is conducted by Daniel Hommes, MD, PhD, director, clinical care and clinical research, UCLA Center for Inflammatory Bowel Diseases. IRB #16-001499, Approved through 10/13/17
If you have any questions or would like to participate, please contact Miriam Dvorsky at mdvorsky@mednet.ucla.edu or 310-206-3778
Do you feel that your food cravings are taking over your New Year's resolution of eating healthier? If so, you can participate in a study to test the ability of a new therapy to control your food cravings.
To be eligible you must be:
Eligible participants will complete 11 visits over a period of four months where they will:
This study is conducted by Claudia Sanmiguel, MD, UCLA Ingestive Behavior and Obesity Program.
If you have questions or would like to participate, please contact Jean Stains, RN at 310-206-1758 or jstains@mednet.ucla.edu IRB # 15-001929, Approved through 2/22/18
The primary objective of this study is to measure how patients perceived their experience during the course of their colonoscopy. Specifically how one would rate three different categories; the quality of the colonoscopy, the experience during the colonoscopy and any procedure related complications.
Participation involves:
Value-based health care, a concept evolving with the landscape of healthcare today, incorporates key concepts including clinical outcomes, patient value and the associated costs of care. The quality quotient or vQ, defined by patient value over disease-related costs, has been used in patients with inflammatory bowel disease as an outcome measure aligned with value-based health care systems. This concept can similarly be translated to other disease states as well as preventive health testing. In colorectal cancer screening, patient value consists of (1) a thorough and adequate screen based off of various nationally-recognized quality metrics including adenoma detection rates, cecal intubation rates, and bowel preparation adequacy; (2) patient experience surrounding their colonoscopy as assessed by GHAA-9 questionnaire; and (3) procedure-related complications. However, each category carries different weight depending on patient preferences. This weight per category is unknown. Hence, the aim of this study is to quantify patient value and to determine the relative importance of each of the three categories noted. Additionally, to truly define vQ in those undergoing CRC screening, procedure-related direct and indirect costs will be assessed in relation to patient value.
This study is conducted by Daniel Hommes, MD, PhD, medical director of the the UCLA Center for Inflammatory Bowel Diseases and director of the GI Quality Program.
If you have questions or would like to participate, please contact Miriam Dvorsky at 310-206-3778 or mdvorsky@mednet.ucla.edu. IRB # 14-001440
We know the struggles of chronic disease can be difficult and can affect one's work productivity. Through this study, we ask for your help in understanding how coping with inflammatory bowel disease affects the daily lives of both the patient and his/her caregiver(s) in and how we can help improve life for both. The UCLA IBD patient-caregiver study will educate doctors, nurses, and the health care team to understand both the patient's and their caregivers' point of view in order to accommodate and to assure future quality care. Participants and their caregivers will be asked to do a 5-10-minute survey. A simple link via email will be sent to any willing participants to do at their convenience. Or, we would be happy to meet with the patients during their clinic visit.
If you have questions or would like to participate, please call Miriam Dvorsky or Dr. Aria Zand at 310-206-3778 or email them at mdvorsky@mednet.ucla.edu and azand@mednet.ucla.edu
IRB #15-001304
You may qualify to participate in a UCLA research study conducted by Dr. Jennifer Labus and Dr. Andrea Rapkin. The purpose of this study is to better understand the physiology and genetic makeup of vulvodynia in order to develop more effective treatments.
If interested, please call (310) 825-5255 or check out our website at: http://www.uclacns.org
Protocol ID: IRB #13-001113 UCLA IRB Approval Date: 3/10/2016 through: 3/9/2017 Committee: Medical IRB 3
If you are a woman thinking about weight loss surgery, you may be eligible to participate in this research study. The purpose of the study is to explore the role that the brain activity -related to appetite, eating habits and food preferences- plays in weight loss after bariatric surgery and if a brain MRI could predict who will be successful in losing weight after surgery.
This study is conducted by Dr. Claudia Sanmiguel, from the UCLA Program for Ingestive Behavior and Obesity and by Drs. Erik Dutson and Yijun Chen, from the UCLA Center for Obesity and METabolic Health (COMET).
If interested, please call (310) 206-1758 or (310) 825-3287.
Protocol ID: IRB#13-001552 UCLA IRB Approved Date: 10/9/2015 through 8/10/2017 Committee: Medical IRB 3
Are you interested in a non-invasive, non-drug therapy for mood symptoms? The purpose of this study is to learn more about anxiety and/or depression and is conducted by Dr. Kirsten Tillisch at the G. Oppenheimer Center for Neurobiology of Stress and Resilience.
If interested, please call (310) 206-8545.
Protocol ID:IRB#15-001639 UCLA IRB Approved Approval Date: 2/19/2016 through 2/10/2017 Committee: Medical IRB 3
If you are a male or female 18 years old referred for endoscopic retrograde cholangiopancreatography (ERCP), you may be eligible to participate in this research study. The study will evaluate the efficacy of different endoscopic techniques that may help cannulate the bile duct during ERCP. We aim at defining the best endoscopic method that should be utilized for patients that are difficult to cannulate during ERCP.
Inclusion/Exclusion Criteria:
This study is conducted by Dr. V. Raman Muthusamy. The study is coordinated by Amanda Moralde.
If interested, please call (310) 267-3636.
Protocol ID: IRB# 14-001221
If you are a male or female >50 years old undergoing screening colonoscopy and have a Smartphone that you are able to operate, you may be eligible to participate in this research study. The study will evaluate the utility of a mobile application to help patients prepare for their anticipated colonoscopy. We hope that the application will be a useful tool that allow the patients to best prepare for their colonoscopy.
Inclusion/Exclusion Criteria:
This study is conducted by Dr. V. Raman Muthusamy. The study is coordinated by Amanda Moralde.
If interested, please call (310) 267-3636.
Protocol ID: IRB# 14-001519
Vedolizumab was recently approved by the FDA, it is a humanized monoclonal antibody that recognizes specifically the a4?7-integrin, a cell-surface mucosal addressin cell adhesion molecule 1 (MAdCAM-1) on the intestinal vasculature. By inhibiting the interaction of a4?7 and MAdCAM-1 Vedolizumab is expected to block lymphocyte trafficking to the intestinal mucosa of IBD patients. Our aim is to evaluate the efficacy of circulating (serum) microRNAs as biomarkers in UC and Crohn's patients following Vedolizumab treatment and examine the mucosal gene expression profile in UC and Crohn's patients following Vedolizumab treatment.
This is a 5 visit study; at the screening visit patients will discuss a medication change to Vedolizumab due to failing or been intolerant to 5-ASA, 6MP or Azathioprine. The baseline visit includes a colonoscopy or flexible sigmoidoscopy prior to starting Vedolizumab. At week 2 and week 6 after starting Vedolizumab patients will have a blood draw only. After 10 weeks of Vedolizumab patients will return for a follow-up scope to measure mucosal healing. All visits are standard of care with the exception of the 10 week post scope visit which is covered by the study.
Principal Investigator: Daniel Hommes, MD, PhD
If interested please call 310-206-9232 or DOMIBD@mednet.ucla.edu
This is a prospective, randomized controlled trial comparing two strategies of post discharge care in patients with cirrhosis-related hospitalizations. Patients meeting the inclusion criteria will be randomized to either the Vivify Home Monitoring kit or standard of care. Those going home with the Vivify kit will for 30 days log on to the tablet and following the prompts input their weight, blood pressure, temperature, heart rate and pulse oximetry. The patient and/or family members will be trained on the kit before discharge. Abnormal question responses and vital sign parameters are associated with medium or high alerts that will be sent to the liver care coordinator. A face to face teleconference call via tablet will be completed for patient assessment and appropriate triage according to the protocol. In the case where the patient's symptoms require urgent care the patient will be directed to the emergency department. Those patients randomized to standard of care will be discharged with contact phone numbers and a return to clinic appointment in 30 days. All patients will fill out questionnaires measuring their quality of life, work productivity health status and medication adherence.
This study is offered at patients admitted at UCLA Ronald Reagan Hospital and the VA Medical Center where we aim to enroll 120 patients.
Primary objective: To demonstrate that care incorporating home monitoring and liver care coordination program will decrease 30-day readmission rates as compared to conventional care.
Principal Investigator: Daniel Hommes, MD, PhD
Sponsor: Vivify Health Inc.
If interested please call 310-206-9232 or DOMIBD@mednet.ucla.edu
Preliminary data suggest that cholesterol and retinoid metabolism are tightly linked in these cells, prompting us to examine this relationship in the setting of obesity and diabetes. Specific aims have been developed to test the following hypotheses: 1) Quantifying liver fibrosis as a continuous variable will predict clinically significant outcomes in fatty liver disease related to metabolic syndrome; and 2) In a prospective cohort of patients, quantified liver fibrosis will correlate more strongly with tissue and circulating retinoid metabolites than with other, commonly measured serum markers.
This study offers a major innovation by performing accurate fibrosis quantification without any human intervention or post-analysis correction. In addition, we can test whether subtle differences in quantified fibrosis impact outcome for a given clinical stage of disease severity, possible because we are measuring fibrosis as a continuous variable, not a categorical one. We are using a disease-independent approach to evaluate anti-fibrotic agents in clinical trials and for evaluating other diagnostic markers.
We are also testing whether a novel diagnostic marker, retinoid storage, correlates with liver disease progression in humans. We propose to extend the study to address fatty liver disease, NAFLD/NASH, in the context of adult patients with abnormal liver tests, fatty liver identified on imaging, physical obesity, and diabetes. Clinical variables and outcomes to be recorded and analyzed include: morphology (age, gender, ethnicity, height, weight/BMI, waist circumference and steatosis on imaging studies); biochemistry (glucose intolerance or diabetes, complete blood counts, metabolic panels, liver function tests, cholesterol panels, insulin, and vitamin D levels); clinical outcomes (date of liver disease diagnosis and estimated duration of disease, listing on liver transplant list, occurrence of liver transplant or re-transplant, presence of cancer, and death); medications (current or previous prescribed, herbals, supplements taken for diabetes, dyslipidemia, hypertension, cardiovascular disease, or stroke); and disease exacerbation/modifying factors (presence of other chronic liver diseases such as NASH + HIV, liver toxins such as alcohol consumption, weight gain, or worsening diabetes).
Data will be collected from subjects who complete eight visits over a 24-month period. Assessments will include morphometric measurements, blood collection for laboratory analysis and completion of dietary history report.
This study is conducted by Dr. Simon Beaven and Stephanie Okimoto.
If interested, please contact Dr. Beaven at 310-794-7788 or Stephanie Okimoto at the UCLA Clinical and Translational Research Center (CTRC) at sokimoto@mednet.ucla.edu
Study completion date is March 22, 2017. ClinicalTrials.gov identifier is NCT02348814.
If you are a male or female >18 years old presented for an upper endoscopy with difficulty of swallowing (dysphagia) following radiation exposure or anastomotic surgery, you may be eligible to participate in this research study. The study will compare the response of endoscopic dilation alone, compared to endoscopic dilation combined with corticosteroid (Triamcinolone) injection. We aim at defining the best therapeutic option for each subset of patients.
Inclusion/Exclusion Criteria:
This study is conducted by Dr. V. Raman Muthusamy. The study is coordinated by Amanda Moralde.
If interested, please call (310) 267-3636.
Protocol ID: IRB# 14-001164
Cholangioscopy is an endoscopic technique used for direct visualization of the bile ducts. The new FDA approved digital Spyglass system introduced a digital sensor for better image quality, which will allow for better visualization and diagnosis. If you are a male or female >18 years old referred for the evaluation of biliary strictures (narrowing) or removal of difficult stones, you might be eligible to participate in the study. You must be undergoing ERCP along with DS Spyglass cholangioscopy as part of your clinical care at UCLA. The study will evaluate the clinical safety, feasibility and efficacy of the new Spyglass DS Spyglass cholangioscopy system for diagnostic imaging of biliary tract disorders (particularly those with biliary strictures and stones).
Inclusion/Exclusion Criteria:
This study is conducted by Dr. V. Raman Muthusamy. The study is coordinated by Amanda Moralde.
If interested, please call (310) 267-3636.
Protocol ID: IRB# 16-000341
If you are a male or female >18 years old with a previously confirmed diagnosis of Barrett's esophagus (BE) with intestinal metaplasia or gastroesophageal reflux disease (GERD) symptoms occurring at least once a month for 6 consecutive months, you might be eligible for the study. The study will evaluate a newly-developed minimally invasive cytology collection system (Cytosponge) in the diagnosis of BE. We hope to develop and validate a new minimally-invasive, reliable, diagnostic method that will possibly replace endoscopy as the method used to screen for BE.
Inclusion/Exclusion Criteria:
This study is conducted by Dr. V. Raman Muthusamy. The study is coordinated by Amanda Moralde.
If interested or in case you have any inquiries, please call (310) 267-3636.
Protocol ID: IRB# 15-000626
The team of physicians at the UCLA Asian Liver Program participate in numerous clinical trials. The clinical trials can cover acute liver failure, hepatitis, and more.
To learn more call Val Peacock, RN at (310) 794-6067 or click here to see current UCLA Asian Liver Program clinical trials »
